Topgenebio strictly adheres to ICH, NMPA , FDA and other regulatory guidelines, providing GLP-compliant genotoxicity evaluation services including the Ames test, Mini Ames test, micronucleus tests in mice and rats, and chromosome aberration test. We have successfully supported IND filings for multiple small molecules and cell and gene therapy products, meeting the requirements for dual filing in both NMPA and FDA, and helping clients accurately assess the mutagenicity and potential carcinogenic risk of their drug candidates.